List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
Despite many companies considering digital transformation a top priority, research shows that 70% of digital transformation initiatives fail. In this ebook, we explore why and how the right approach can see your organisation succeed.
Researchers have developed kidney organoids that resemble the collecting duct system, using ureteric bud progenitor cells.
A new magnetically driven rotary microfilter has been developed to filter particles inside a lab-on-a-chip microfluidic device.
This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being used in covalent fragment screening and the challenges and opportunities presented by automation in the life sciences. Also in this issue are features on stem cells, antibodies and hit-to-lead.
Learn what sets Bethyl custom monoclonal antibodies quality and service apart and discover the top reasons why you should choose Forits Life Sciences for your next project.
Complete solutions for neurological disease research and discovery - helping you to better understand diseases to improve patient outcomes.
A screening method called dynamic BH3 profiling can identify potentially effective combinations of existing drugs for personalised cancer therapy, research has shown.
Scientists have found four clinically approved drugs and nine compounds with the potential to be repurposed as therapeutics for COVID-19.
We discuss how liquid handling automation supports drug discovery workflows & highlight opportunities to improve the efficiency and quality of these.
A new high-throughput screening platform has been used to identify two compounds with antiviral activity against the Nipah and Hendra viruses.
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
A modified luciferase enzyme has been developed as an immunosensor to be fused with a Q-body and used in immunoassays.
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
A wide range of tools to support your immuno-oncology research and help redefine and develop tailored, life-changing immunotherapies to fight cancer.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
